摘要
选择 94例慢性丙型病毒性肝炎 (慢性丙肝 )患者 ,采用 α2 b-干扰素 ( α2 b- IFN)治疗 ,动态检测其血清抗 - HCV、 HCV- RNA及α2 b- IFN- Ig G表达水平。结果显示α2 b- IFN治疗后抗 - HCV、 HCV- RNA阴转率分别为3 2 .98% ( 3 1/ 94)和 3 8.3 0 % ( 3 6/ 94) ,常规治疗组治疗后抗 - HCV、HCV- RNA阴转率分别为 10 .0 0 % ( 4/ 40 )和15 .0 0 % ( 6/ 40 ) ,两者相比差异有显著性 ( P<0 .0 1)。α2 b- IFN治疗后抗 - IFN- Ig G阳检率为 5 .3 2 % ( 5 / 94) ,与常规治疗组相比差异无显著性 ( P >0 .0 5 )。认为α2 b- IFN对抗 - HCV、 HCV- RNA阴转具有肯定疗效 ,且优于常规治疗 ,是治疗慢性丙肝的有效药物之一。α2 b- IFN虽有一定的免疫原性 ,但在治疗过程中仅诱导机体产生低水平的抗α2 b- IFN- Ig G,对 IFN-α2
The levels of anti-HCV,HCV-RNA and anti-α2b-IFN-IgG in serum of 94 patients with chronic hepatitis C,which was treated with α2b-IFN were respectively detected in different course of treatment.After the treatment of α2b-IFN and routine medicine,the total negative rates of anti-HCV,HCV-RNA were 32.98%(31/94),38.30%(36/94) and 10.00%(4/40),15.00%(6/40) respectively.There was high significant difference between two treatment groups (P<0.01).After the treatment of α2b-IFN,the total positive rate of anti-α2b-IFN-IgG was 5.32%(5/94).There was no significant difference between two treatment groups (P>0.05).α2b-IFN has definitive curative effect for the patients with chronic hepatitis C and its therapy effect is better than that of routine treatment.α2b-IFN can be regarded as one of the effective medicine for the patients with chronic hepatitis C.Although α2b-IFN has certain antigenicity,few anti-α2b-IFN-IgG can be induced in the course of treatment and the restrain effect of anti-α2b-IFN-IgG on the further treatment of α2b-IFN is light.
出处
《山东医药》
CAS
北大核心
2003年第10期1-3,共3页
Shandong Medical Journal
基金
安徽省教育厅自然科学基金重点项目 ( No.2 0 0 3kj0 2 7zd)
